Nocardia farcinica Brain Abscess in a Glucocorticoid-Treated Patient with Giant-Cell Arteritis: A Case Report

23 November 2025 : Case report Japan

Adverse events of drug therapy, Rare coexistence of disease or pathology

Simon Valenti

^{ABCDEF 1}, Masahiro Kogami

^{DE 2*}, Mai Suzuki^{CDE 1}, Toshio Naito

^{E 1}, Naoto Tamura^{E 2}

DOI: 10.12659/AJCR.949616

Am J Case Rep 2025; 26:e949616

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Susceptibility of Nocardia farcinica against antimicrobial agents.

Antimicrobial agents	MIC (μg/mL)	Value	Range
Ceftriaxone	>32	R	1–32
Cefotaxime	>32	R	1–32
Minocycline	2	I	0.5–4
Levofloxacin	4	R	0.5–4
Moxifloxacin	2	I	0.5–4
Linezolid	≤2	S	2–16
Amikacin	≤4	S	4–32
Imipenem	≤2	S	2–16
Tobramycin	8	I	1–8
Clarithromycin	>8	R	1–8
Sulfamethoxazole-trimethoprim	≤9.5/0.5	S	9.5/0.5–38/2
S – susceptible; I – intermediate; R – resistant (according to clinical and laboratory results). Standards Institute M24-A2 Ed3 and interpreted by M62 Ed1). MIC – minimum inhibitory concentration.

Back to the Article